Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
2003 3
2004 4
2005 4
2006 11
2007 9
2008 13
2009 12
2010 18
2011 15
2012 19
2013 21
2014 26
2015 48
2016 62
2017 45
2018 57
2019 61
2020 71
2021 64
2022 41
2023 35
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

543 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Age-related macular degeneration therapy: a review.
Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Ammar MJ, et al. Among authors: ho ac. Curr Opin Ophthalmol. 2020 May;31(3):215-221. doi: 10.1097/ICU.0000000000000657. Curr Opin Ophthalmol. 2020. PMID: 32205470 Review.
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Heier JS, et al. Among authors: ho a. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Ophthalmology. 2012. PMID: 23084240 Clinical Trial.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Reply.
Huang D, Starr MR, Kaiser RS, Mehta S, Park CH, Khan MA, Gupta OP, Kuriyan AE, Yonekawa Y, Ho AC, Garg SJ, Cohen MN, Hsu J. Huang D, et al. Among authors: ho ac. Retina. 2023 Mar 1;43(3):e16-e17. doi: 10.1097/IAE.0000000000003701. Retina. 2023. PMID: 36729563 No abstract available.
Reply.
Soares RR, Sharpe J, Zhang Q, Ho AC, Yonekawa Y, Hsu J. Soares RR, et al. Among authors: ho ac. Ophthalmology. 2024 Mar;131(3):e9-e10. doi: 10.1016/j.ophtha.2023.11.015. Epub 2023 Dec 20. Ophthalmology. 2024. PMID: 38127039 No abstract available.
Reply.
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, Dugel PU. Gonzalez VH, et al. Among authors: ho ac. Am J Ophthalmol. 2017 May;177:231-232. doi: 10.1016/j.ajo.2017.02.009. Epub 2017 Mar 23. Am J Ophthalmol. 2017. PMID: 28342529 No abstract available.
543 results